Cyclosporine
- Generic Name
- Cyclosporine
- Brand Names
- Cequa, Gengraf, Neoral, Restasis, Sandimmune, Verkazia, Vevye, Ikervis
- Drug Type
- Small Molecule
- Chemical Formula
- C62H111N11O12
- CAS Number
- 59865-13-3
- Unique Ingredient Identifier
- 83HN0GTJ6D
- Background
Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus Beauveria nivea. Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novar...
- Indication
Cyclosporine is approved for a variety of conditions. Firstly, it is approved for the prophylaxis of organ rejection in allogeneic kidney, liver, and heart transplants. It is also used to prevent bone marrow transplant rejection. For the above indications, cyclosporine can be used in conjunction with azathioprine and corticosteroids. Finally, cyclosporine ca...
- Associated Conditions
- Atopic Dermatitis, Bone Marrow Transplant Rejection, Chronic transplant rejection, Connective Tissue Disorders, Dry Eyes, Graft-versus-host Disease (GVHD), Heart Transplant Rejection, Immune Thrombocytopenia (ITP), Interstitial Cystitis, Juvenile Idiopathic Arthritis (JIA), Kidney Transplant Rejection, Liver Transplant Rejection, Lupus Nephritis, Nephrotic Syndrome, Ocular Rosacea, Rheumatoid Arthritis, Severe Ulcerative Colitis, Steroid Dependent Nephrotic Syndrome, Steroid Resistant Nephrotic Syndrome, Uveitis, Vernal Keratoconjunctivitis, Blistering disorder, Refractory Ulcerative colitis, Severe Psoriasis, Severe, active Rheumatoid arthritis, Severe, recalcitrant Plaque psoriasis, Suppressed tear production
- Associated Therapies
- -
Study of Total Body Irradiation and Fludarabine Followed By Allogeneic Peripheral Blood Stem Cell or Bone Marrow Transplantation in Combination With Cyclosporine and Mycophenolate Mofetil in Patients With Inherited Disorders
- Conditions
- First Posted Date
- 2001-02-02
- Last Posted Date
- 2014-12-09
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT00010361
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Total-Body Irradiation Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients With Severe Combined Immunodeficiency Undergoing Donor Bone Marrow Transplant
- Conditions
- Interventions
- First Posted Date
- 2001-01-08
- Last Posted Date
- 2019-07-29
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 6
- Registration Number
- NCT00008450
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma
- Conditions
- Interventions
- Drug: Myeloma Immunoglobulin Idiotype VaccineDrug: BortezomibDrug: CyclophosphamideBiological: GMCSF (granulocyte macrophage colony stimulating factor)Drug: CyclosporineDrug: Doxorubicin hydrochlorideDrug: EtoposideDrug: Fludarabine phosphateDrug: PrednisoneDrug: Vincristine SulfateDrug: MethotrexateBiological: GCSF (granulocyte colony stimulating factor)
- First Posted Date
- 2000-08-24
- Last Posted Date
- 2017-10-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 20
- Registration Number
- NCT00006184
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Antithymocyte Globulin and Cyclosporine to Treat Myelodysplasia
- Conditions
- Interventions
- First Posted Date
- 2000-07-07
- Last Posted Date
- 2014-10-23
- Lead Sponsor
- Neal Young, M.D.
- Target Recruit Count
- 42
- Registration Number
- NCT00005937
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Mycophenolate Mofetil and Cyclosporine to Treat Relapsing Aplastic Anemia
- Conditions
- First Posted Date
- 2000-07-07
- Last Posted Date
- 2008-03-04
- Target Recruit Count
- 130
- Registration Number
- NCT00005935
- Locations
- 🇺🇸
National Heart, Lung and Blood Institute (NHLBI), Bethesda, Maryland, United States
Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases
- First Posted Date
- 2000-07-06
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Fairview University Medical Center
- Target Recruit Count
- 10
- Registration Number
- NCT00006055
- Locations
- 🇺🇸
Fairview University Medical Center, Minneapolis, Minnesota, United States
Pilot Study of Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients With Life Threatening Hemophagocytic Disorders
- First Posted Date
- 2000-07-06
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Fairview University Medical Center
- Target Recruit Count
- 40
- Registration Number
- NCT00006056
- Locations
- 🇺🇸
Fairview University Medical Center, Minneapolis, Minnesota, United States
Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies
- Conditions
- Immunologic Deficiency SyndromesChediak-Higashi SyndromeCommon Variable ImmunodeficiencyGraft Versus Host DiseaseX-Linked Lymphoproliferative SyndromeFamilial Erythrophagocytic LymphohistiocytosisHemophagocytic LymphohistiocytosisX-linked AgammaglobulinemiaWiskott-Aldrich SyndromeChronic Granulomatous Disease
- First Posted Date
- 2000-07-06
- Last Posted Date
- 2009-10-15
- Lead Sponsor
- Fairview University Medical Center
- Registration Number
- NCT00006054
- Locations
- 🇺🇸
Fairview University Medical Center, Minneapolis, Minnesota, United States
Phase I/II Study of Total Body Irradiation, Cyclophosphamide, and Fludarabine Followed by Alternate Donor Hematopoietic Cell Transplantation in Patients With Fanconi's Anemia
- Conditions
- First Posted Date
- 2000-06-05
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- University of Minnesota
- Target Recruit Count
- 30
- Registration Number
- NCT00005898
- Locations
- 🇺🇸
University of Minnesota Cancer Center, Minneapolis, Minnesota, United States
Comparing Therapies for the Treatment of Severe Aplastic Anemia
- Conditions
- Interventions
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2020-09-22
- Target Recruit Count
- 33
- Registration Number
- NCT00001626
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.